Log in or Sign up for Free to view tailored content for your specialty!
Cirrhosis/Liver Failure News
Trial of emricasan to use BreathID to monitor patients with NASH
Exalenz Bioscience announced a collaboration with Conatus Pharmaceuticals Inc. to use the BreathID Methacetin Breath Test to monitor patients in a phase2b trial evaluating emricasan, according to a press release.
Combatting antimicrobial resistance critical for patients with cirrhosis
Log in or Sign up for Free to view tailored content for your specialty!
Portal hypertensive gastropathy a prognostic factor for cirrhosis
The correlation between portal hypertensive gastropathy and portal hypertension was strong enough to suggest which patients with these conditions could develop cirrhosis, but not hepatocellular carcinoma, according to research published in BMC Gastroenterology.
Universal bilirubin screening limited by economic disparities
The increase in follow-up care due to universal bilirubin screening in Canadian newborns was limited by socioeconomic disparities, according to recent findings published in Academic Pediatrics.
Epilepsy linked to hepatic encephalopathy in patients with cirrhosis
Patients with cirrhosis and epilepsy are at higher risk for hepatic encephalopathy, according to research published in BMC Gastroenterology.
PPIs increase risk for hepatic encephalopathy, spontaneous bacterial peritonitis
Proton pump inhibitors increased the risk for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis and ascites, according to recent findings published in Hepatology.
New model can identify in-hospital mortality of patients with SBP
Researchers from Barcelona developed a model that predicted the in-hospital mortality of patients with spontaneous bacterial peritonitis at a sensitivity of 0.85 and specificity of 0.75, according to recent findings published in Alimentary Pharmacology & Therapeutics. The model includes Child-Pugh score, serum urea, blood leukocyte count and mean arterial pressure.
Obeticholic acid reduces ALP and bilirubin in primary biliary cirrhosis
Obeticholic acid reduced alkaline phosphatase and bilirubin levels in patients with primary biliary cholangitis, according to a phase 3 study published in The New England Journal of Medicine. However, patients taking the drug were more likely to experience pruritis.
Systemic inflammation drives acute-on-chronic liver failure
Recent data published in Hepatology suggest systematic inflammation as the main driver of acute-on-chronic liver failure in patients with decompensated cirrhosis.
Patients with diabetes, cirrhosis at greater risk for HCC
Having non-hepatitis C virus cirrhosis and diabetes puts patients at a higher risk for developing hepatocellular carcinoma, according to research recently published in The American Journal of Gastroenterology.
-
Headline News
‘Please talk about it’: Patients with heart disease want more guidance on sexual health
November 26, 20242 min read -
Headline News
Breast calcification on mammogram ‘especially predictive’ of CVD risk in younger women
November 26, 20243 min read -
Headline News
Q&A: How to talk to families about vaccines
November 26, 20245 min read
-
Headline News
‘Please talk about it’: Patients with heart disease want more guidance on sexual health
November 26, 20242 min read -
Headline News
Breast calcification on mammogram ‘especially predictive’ of CVD risk in younger women
November 26, 20243 min read -
Headline News
Q&A: How to talk to families about vaccines
November 26, 20245 min read